UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

Investigational new drugs, 2019-04, Vol.37 (2), p.297-306

2019

Volltextzugriff (PDF)

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions

Nature immunology, 2017-08, Vol.18 (8), p.889-898

2017

Volltextzugriff (PDF)

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Nature medicine, 2002-01, Vol.8 (1), p.68-74

2002

Volltextzugriff (PDF)

Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia

European journal of haematology, 2024-01, Vol.112 (1), p.51-63

2024

Volltextzugriff (PDF)

Lenalidomide for the treatment of B-cell lymphoma

Expert opinion on investigational drugs, 2016-09, Vol.25 (9), p.1103-1116

2016

Volltextzugriff (PDF)

Blinatumomab: a historical perspective

Pharmacology & therapeutics (Oxford), 2012-12, Vol.136 (3), p.334-342

2012

Volltextzugriff (PDF)

Multidisciplinary Diagnostic Approach in Intraocular Lymphoma Featuring Pseudo-hypopyon: Case Series and Literature Review

Ocular immunology and inflammation, 2021-04, Vol.29 (3), p.490-495

2021

Volltextzugriff (PDF)

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Leukemia & lymphoma, 2022-01, Vol.63 (1), p.243-246

2022

Volltextzugriff (PDF)

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

The Lancet (British edition), 2021-03, Vol.397 (10277), p.892-901

2021

Volltextzugriff (PDF)

Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version

Annals of hematology, 2023-08, Vol.102 (8), p.2279-2282

2023

Volltextzugriff (PDF)

Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy

Leukemia & lymphoma, 2016-06, Vol.57 (6), p.1335-1341

2016

Volltextzugriff (PDF)

Senescence-associated reprogramming promotes cancer stemness

Nature (London), 2018-01, Vol.553 (7686), p.96-100

2018

Volltextzugriff (PDF)

Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development

Expert opinion on drug discovery, 2017-07, Vol.12 (7), p.733-745

2017

Volltextzugriff (PDF)

Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy

Immunotherapy, 2019-03, Vol.11 (4), p.265-272

2019

Volltextzugriff (PDF)

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Advances in therapy, 2017-10, Vol.34 (10), p.2232-2273

2017

Volltextzugriff (PDF)

Primary diffuse large B-cell lymphoma of the stomach

Critical reviews in oncology/hematology, 2007-07, Vol.63 (1), p.65-71

2007

Volltextzugriff (PDF)

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma

Hematological oncology, 2022-08, Vol.40 (3), p.356-369

2022

Volltextzugriff (PDF)

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

Nature reviews. Clinical oncology, 2017-04, Vol.14 (4), p.203-220

2017

Volltextzugriff (PDF)

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

Nature (London), 2013-09, Vol.501 (7467), p.421-425

2013

Volltextzugriff (PDF)

Tumor mass in the palate after bone marrow transplantation

Oral surgery, oral medicine, oral pathology and oral radiology, 2017-08, Vol.124 (2), p.107-113

2017

Volltextzugriff (PDF)

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

The lancet oncology, 2018-05, Vol.19 (5), p.649-659

2018

Volltextzugriff (PDF)

Helicobacter pylori and Gastric lymphoma: High seroprevalence of CagA in diffuse large b-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type

The American journal of gastroenterology, 2001-08, Vol.96 (8), p.2324-2328

2001

Volltextzugriff (PDF)

molecular background of aggressive B cell lymphomas as a basis for targeted therapy

The Journal of pathology, 2011, Vol.223 (2), p.275-283

2011

Volltextzugriff (PDF)

Enhancer of zeste homolog 2 (EZH2) inhibitors

Leukemia & lymphoma, 2018-07, Vol.59 (7), p.1574-1585

2018

Volltextzugriff (PDF)

Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder

The American journal of surgical pathology, 2007-09, Vol.31 (9), p.1344-1350

2007

Volltextzugriff (PDF)

1 – 25 von 7.642

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.384)
Mit Volltextzugriff
(4.540)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(7.296)
Science & Technology
(5.774)
Life Sciences & Biomedicine
(5.740)
Male
(3.753)
Female
(3.480)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(2.987)
Oncology
(2.903)
Middle Aged
(2.884)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2.493)
Aged
(2.489)
Hematology
(2.411)
Adult
(2.135)
Lymphoma, B-Cell - Drug Therapy
(1.734)
Treatment Outcome
(1.507)
Rituximab
(1.456)
Lymphoma
(1.422)
Biological And Medical Sciences
(1.212)
Medical Sciences
(1.205)
Antineoplastic Agents - Therapeutic Use
(1.199)
Lymphoma, Large B-Cell, Diffuse - Pathology
(1.130)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(7.480)
IngentaConnect
(3.031)
Ovid SocietyJournals and Single Titles
(2.887)
Elsevier ScienceDirect Journals Complete
(1.507)
Springer Nature - Complete Springer Journals
(1.314)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.183)
Taylor & Francis Journals
(1.101)
Taylor & Francis 数据库
(1.100)
Taylor & Francis Online
(969)
Single Journals
(932)
Wiley Online Library - AutoHoldings Journals
(907)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(878)
Wiley Online Library Full Collection 2018
(830)
IngentaConnect Journals
(661)
Nexis Uni
(175)
SAGE Complete
(128)
Nature
(103)
Oxford Journals
(87)
Thieme Connect Journals
(80)
Psychology & Behavioral Sciences Collection
(79)
Free E-Journal (出版社公開部分のみ）
(0)

16 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Leukemia & Lymphoma
(731)
Annals Of Hematology
(285)
Rinshō Ketsueki
(170)
International Journal Of Hematology
(163)
Rinsho Ketsueki
(162)
Clinical Lymphoma, Myeloma And Leukemia
(159)
European Journal Of Haematology
(150)
Hematological Oncology
(131)
Leukemia Research
(129)
Journal Of Pediatric Hematology/oncology
(101)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(27)

Menü

Weitere Dienste

Einstellungen

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia

Lenalidomide for the treatment of B-cell lymphoma

Blinatumomab: a historical perspective

Multidisciplinary Diagnostic Approach in Intraocular Lymphoma Featuring Pseudo-hypopyon: Case Series and Literature Review

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version

Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy

Senescence-associated reprogramming promotes cancer stemness

Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development

Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Primary diffuse large B-cell lymphoma of the stomach

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

Tumor mass in the palate after bone marrow transplantation

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Helicobacter pylori and Gastric lymphoma: High seroprevalence of CagA in diffuse large b-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type

molecular background of aggressive B cell lymphomas as a basis for targeted therapy

Enhancer of zeste homolog 2 (EZH2) inhibitors

Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder

Aktive Filter

Suchergebnisse filtern